CommentaryPublished 21 May 2016
ROR1 is an Intriguing Target for Cancer Therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) is an oncofetal protein and has gained attention in cancer therapy since its initial discovery as a relatively specific surface antigen on B cell chronic lymphocytic leukemia (CLL) in 2008. The list of cancer types with ROR1 expression keeps growing, comprising, among others, malignant melanoma, breast cancer, and prostate cancer. It has been shown that ROR1 mediates several oncogenic pathways in a cancer type- and context-dependent manner. There are several ways to target ROR1 molecule, some of which have been in preclinical and clinical trials. We briefly summarize the oncogenic signaling pathways related to ROR1, as well as the update on ROR1-targeted therapies.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMolecular Enzymology and Drug Targets
- SubjectBiochemistry & Biotechnology
- SubjectGenetics & Molecular Biology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ryan Kolb”
- BylineArticles whose byline prints “Paige Kluz”
- BylineArticles whose byline prints “Weizhou Zhang”
